Tag - ACHN

Developments

EMA grants Achillion danicopan PRIME designation

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received the European Medicines Agency’s (EMA) priority medicines, or PRIME, designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The EMA’s...

November 19, 2019

Developments

Achillion gets FDA breakthrough therapy designation for danicopan

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received FDA breakthrough therapy designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood cells in...

September 25, 2019

Developments

Achillion reports positive interim Phase 2 data in paroxysmal nocturnal hemoglobinuria

Achillion Pharmaceuticals (NASDAQ:ACHN) reported interim data from its Phase 2 trial of ACH-4471, in combination with eculizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement...

May 17, 2019

Tag - ACHN

EMA grants Achillion danicopan PRIME designation

Achillion gets FDA breakthrough therapy designation for danicopan

Achillion reports positive interim Phase 2 data in paroxysmal nocturnal hemoglobinuria

General

More